Free Trial
→ Utah’s New Oil Find (From Stansberry Research) (Ad) Buy VERV Stock  Free VERV Stock Alerts

Verve Therapeutics (VERV) Financials

Verve Therapeutics logo
$11.06 -0.06 (-0.54%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$11.03 -0.03 (-0.27%)
As of 06/20/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Verve Therapeutics

Annual Income Statements for Verve Therapeutics

This table shows Verve Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -25 -46 -120 -157 -200 -199
Consolidated Net Income / (Loss)		 -19 -46 -120 -157 -200 -199
Net Income / (Loss) Continuing Operations		 -25 -46 -120 -157 -200 -199
Total Pre-Tax Income 		-19 -46 -120 -157 -200 -198
Total Operating Income		 -14 -41 -87 -166 -223 -229
Total Gross Profit		 0.00 0.00 0.00 1.94 12 32
Total Revenue		 0.00 0.00 0.00 1.94 12 32
Operating Revenue		 - 0.00 0.00 1.94 12 32
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 14 41 87 168 235 261
Selling, General & Admin Expense		 2.50 5.26 19 38 50 57
Research & Development Expense		 11 35 68 130 185 204
Total Other Income / (Expense), net		 -5.66 -5.08 -33 8.35 23 30
Other Income / (Expense), net		 -5.66 -5.08 -33 8.35 23 30
Income Tax Expense		 - 0.00 0.00 0.05 0.28 0.35
Basic Earnings per Share		 ($15.11) ($20.31) ($4.48) ($2.91) ($3.12) ($2.35)
Weighted Average Basic Shares Outstanding		 1.28M 2.25M 26.87M 54.02M 64.18M 84.72M
Diluted Earnings per Share		 ($15.11) ($20.31) ($4.48) ($2.91) ($3.12) ($2.35)
Weighted Average Diluted Shares Outstanding		 1.28M 2.25M 26.87M 54.02M 64.18M 84.72M
Weighted Average Basic & Diluted Shares Outstanding		 1.28M 2.25M 26.87M 61.83M 83.62M 88.80M

Quarterly Income Statements for Verve Therapeutics

This table shows Verve Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -45 -41 -52 -55 -46 -48 -49 -50 -48 -52 -31
Consolidated Net Income / (Loss)		 -45 -41 -52 -54 -46 -48 -49 -50 -50 -50 -31
Net Income / (Loss) Continuing Operations		 -45 -41 -52 -54 -46 -48 -49 -50 -50 -50 -31
Total Pre-Tax Income 		-45 -41 -52 -54 -46 -48 -49 -50 -50 -50 -31
Total Operating Income		 -44 -48 -58 -59 -52 -54 -57 -59 -57 -56 -37
Total Gross Profit		 0.93 1.01 1.40 2.09 3.12 5.14 5.70 6.69 6.87 13 33
Total Revenue		 0.93 1.01 1.40 2.09 3.12 5.14 5.70 6.69 6.87 13 33
Operating Revenue		 0.93 1.01 1.40 2.09 3.12 5.14 5.70 6.69 6.87 13 33
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 45 49 60 61 55 59 63 66 64 69 70
Selling, General & Admin Expense		 9.59 11 13 13 12 12 14 15 14 14 15
Research & Development Expense		 35 37 47 47 44 47 48 51 50 55 54
Total Other Income / (Expense), net		 -1.33 6.68 6.28 4.78 6.64 5.63 8.21 9.10 6.88 6.11 5.68
Other Income / (Expense), net		 -1.33 6.68 6.28 4.78 6.64 5.63 8.21 9.10 6.88 6.11 5.68
Income Tax Expense		 0.00 - 0.00 0.18 0.07 0.03 0.11 0.07 0.10 0.07 0.08
Basic Earnings per Share		 ($0.79) ($0.66) ($0.84) ($0.87) ($0.72) ($0.69) ($0.59) ($0.59) ($0.59) ($0.58) ($0.35)
Weighted Average Basic Shares Outstanding		 57.21M 54.02M 61.79M 61.95M 63.21M 64.18M 83.13M 84.23M 84.63M 84.72M 88.80M
Diluted Earnings per Share		 ($0.79) ($0.66) ($0.84) ($0.87) ($0.72) ($0.69) ($0.59) ($0.59) ($0.59) ($0.58) ($0.35)
Weighted Average Diluted Shares Outstanding		 57.21M 54.02M 61.79M 61.95M 63.21M 64.18M 83.13M 84.23M 84.63M 84.72M 88.80M
Weighted Average Basic & Diluted Shares Outstanding		 61.60M 61.83M 61.93M 63.72M 63.75M 83.62M 83.97M 84.62M 84.66M 88.80M 89.14M

Annual Cash Flow Statements for Verve Therapeutics

This table details how cash moves in and out of Verve Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -2.25 6.24 73 51 91 -34
Net Cash From Operating Activities		 -7.44 -35 -78 -122 -150 -158
Net Cash From Continuing Operating Activities		 -7.44 -35 -65 -122 -150 -158
Net Income / (Loss) Continuing Operations		 -19 -46 -120 -157 -200 -199
Consolidated Net Income / (Loss)		 -19 -46 -120 -157 -200 -199
Depreciation Expense		 0.11 1.33 1.54 2.80 5.46 6.75
Amortization Expense		 -0.07 0.38 1.51 -1.03 -14 -12
Non-Cash Adjustments To Reconcile Net Income		 9.16 6.09 40 25 42 49
Changes in Operating Assets and Liabilities, net		 2.66 2.64 12 8.38 18 -2.26
Net Cash From Investing Activities		 -13 -51 -239 -156 28 75
Net Cash From Continuing Investing Activities		 -13 -51 -239 -156 28 75
Purchase of Property, Plant & Equipment		 -1.86 -3.42 -4.36 -13 -9.28 -3.74
Purchase of Investments		 -22 -98 -371 -479 -517 -424
Sale and/or Maturity of Investments		 11 51 137 337 554 503
Net Cash From Financing Activities		 18 93 377 329 213 49
Net Cash From Continuing Financing Activities		 18 93 377 329 213 49
Repurchase of Common Equity		 - 0.00 -3.63 -0.78 -0.46 -0.07
Issuance of Common Equity		 0.00 0.00 285 328 212 48
Other Financing Activities, net		 -0.09 0.01 1.75 2.18 1.20 1.26

Quarterly Cash Flow Statements for Verve Therapeutics

This table details how cash moves in and out of Verve Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 204 -162 -32 -14 8.28 128 -62 -2.71 17 14 -76
Net Cash From Operating Activities		 -29 -33 -49 -48 -12 -41 -43 -34 -40 -41 -28
Net Cash From Continuing Operating Activities		 -29 -33 -49 -48 -12 -41 -43 -34 -40 -41 -28
Net Income / (Loss) Continuing Operations		 -45 -41 -52 -54 -46 -48 -49 -50 -50 -50 -31
Consolidated Net Income / (Loss)		 -45 -41 -52 -54 -46 -48 -49 -50 -50 -50 -31
Depreciation Expense		 0.72 0.93 1.13 1.34 1.47 1.52 1.63 1.67 1.75 1.70 1.72
Amortization Expense		 -0.12 -2.14 -3.86 -3.70 -3.49 -3.34 -3.97 -3.54 -2.75 -2.16 -1.89
Non-Cash Adjustments To Reconcile Net Income		 9.82 6.85 8.92 11 9.75 12 12 12 13 12 13
Changes in Operating Assets and Liabilities, net		 5.60 2.56 -3.31 -2.98 26 -2.22 -4.04 5.83 -1.12 -2.85 -9.45
Net Cash From Investing Activities		 -56 -168 15 33 -12 -8.89 -42 30 57 30 -48
Net Cash From Continuing Investing Activities		 -56 -168 15 33 -12 -8.89 -42 30 57 30 -48
Purchase of Property, Plant & Equipment		 -2.64 -4.97 -3.38 -2.66 -1.06 -2.19 -0.43 -0.98 -0.94 -1.39 -1.22
Purchase of Investments		 -148 -257 -134 -113 -148 -122 -164 -112 -75 -73 -145
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 95 94 153 149 137 116 123 143 133 104 98
Net Cash From Financing Activities		 288 40 2.04 1.23 32 177 23 1.30 0.01 25 0.01
Net Cash From Continuing Financing Activities		 288 40 2.04 1.23 32 177 23 1.30 0.01 25 0.01
Repurchase of Common Equity		 - -0.18 -0.07 0.07 - - -0.05 0.05 - - 0.00
Issuance of Common Equity		 288 39 1.99 0.62 32 178 22 0.42 - 25 0.00
Other Financing Activities, net		 1.11 0.44 0.12 0.55 0.21 0.32 0.30 0.83 0.01 0.12 0.01

Annual Balance Sheets for Verve Therapeutics

This table presents Verve Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 78 384 679 753 647
Total Current Assets		 74 367 563 638 543
Cash & Equivalents		 8.99 64 115 206 173
Short-Term Investments		 63 296 439 418 352
Prepaid Expenses		 1.85 6.69 7.34 8.10 15
Other Current Assets		 - 0.00 1.01 5.90 3.26
Plant, Property, & Equipment, net		 3.98 7.22 19 23 19
Total Noncurrent Assets		 0.46 9.77 97 92 86
Other Noncurrent Operating Assets		 0.46 9.77 97 92 86
Total Liabilities & Shareholders' Equity		 78 384 679 753 647
Total Liabilities		 17 27 128 153 154
Total Current Liabilities		 7.32 22 35 37 43
Accounts Payable		 0.04 7.08 2.42 6.64 4.52
Accrued Expenses		 7.19 13 21 20 24
Current Deferred Revenue		 0.09 - - 0.00 3.61
Other Current Liabilities		 0.00 1.96 - 10 10
Total Noncurrent Liabilities		 9.85 4.75 93 116 111
Noncurrent Deferred Revenue		 0.13 0.00 20 49 50
Other Noncurrent Operating Liabilities		 9.72 4.75 73 68 61
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 61 357 551 600 493
Total Preferred & Common Equity		 -64 357 551 600 493
Preferred Stock		 125 0.00 0.00 0.00 0.00
Total Common Equity		 -64 357 551 600 493
Common Stock		 2.62 544 896 1,144 1,236
Retained Earnings		 -67 -187 -344 -544 -743
Accumulated Other Comprehensive Income / (Loss)		 0.01 -0.23 -0.69 0.27 0.43

Quarterly Balance Sheets for Verve Therapeutics

This table presents Verve Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 324 673 634 589 612 732 701 664 614
Total Current Assets		 299 562 518 473 498 620 591 556 512
Cash & Equivalents		 73 277 84 70 78 144 141 159 97
Short-Term Investments		 221 274 425 392 407 462 434 381 401
Prepaid Expenses		 5.08 9.99 7.70 8.50 9.89 8.19 12 14 13
Other Current Assets		 - 0.93 1.40 2.09 3.15 5.77 3.04 2.63 1.40
Plant, Property, & Equipment, net		 12 15 21 21 21 21 20 20 18
Total Noncurrent Assets		 13 97 96 95 93 91 90 88 84
Other Noncurrent Operating Assets		 13 97 96 95 93 91 90 88 84
Total Liabilities & Shareholders' Equity		 324 673 634 589 612 732 701 664 614
Total Liabilities		 28 125 125 124 152 149 155 155 141
Total Current Liabilities		 26 29 34 33 35 31 40 43 52
Accounts Payable		 6.32 0.47 3.37 3.15 1.05 3.05 6.83 4.64 5.35
Accrued Expenses		 19 20 19 20 23 17 20 22 17
Current Deferred Revenue		 - - - - - 1.47 3.48 5.72 19
Other Current Liabilities		 - 8.90 11 10 10 10 10 10 11
Total Noncurrent Liabilities		 2.09 96 91 91 117 118 114 113 89
Noncurrent Deferred Revenue		 - 20 20 20 49 52 51 51 30
Other Noncurrent Operating Liabilities		 2.09 76 71 71 69 66 63 62 59
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 296 548 509 465 460 583 546 509 474
Total Preferred & Common Equity		 296 548 509 465 460 583 546 509 474
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 296 548 509 465 460 583 546 509 474
Common Stock		 555 852 906 916 957 1,177 1,190 1,200 1,247
Retained Earnings		 -258 -303 -396 -450 -496 -593 -643 -693 -774
Accumulated Other Comprehensive Income / (Loss)		 -0.94 -0.92 -0.24 -0.75 -0.60 -0.50 -0.62 1.14 0.39

Annual Metrics And Ratios for Verve Therapeutics

This table displays calculated financial ratios and metrics derived from Verve Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 505.77% 174.98%
EBITDA Growth		 0.00% -128.40% -166.55% -32.65% -34.18% 2.26%
EBIT Growth		 0.00% -136.85% -163.25% -30.77% -26.99% 0.72%
NOPAT Growth		 0.00% -197.81% -114.31% -90.30% -34.67% -2.48%
Net Income Growth		 0.00% -136.85% -163.25% -30.81% -27.12% 0.68%
EPS Growth		 0.00% -34.41% 77.94% 35.04% -7.22% 24.68%
Operating Cash Flow Growth		 0.00% -373.86% -120.84% -57.08% -22.25% -5.45%
Free Cash Flow Firm Growth		 0.00% 0.00% -290.93% -84.96% 2.67% -24.18%
Invested Capital Growth		 0.00% 0.00% 71.55% 359.81% -404.53% -26.31%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 108.93% 54.18% 32.53%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -8.45% -3.93% -0.14%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -6.57% -3.79% -0.83%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -10.08% -2.88% -0.94%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -6.60% -3.77% -0.85%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -153.99% -0.97% 4.47%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -20.16% -4.13% -5.49% -0.10%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 4.64% -1.03%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 390.13% 1.65% 1.56%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% -8,014.27% -1,775.13% -630.99%
Operating Margin		 0.00% 0.00% 0.00% -8,536.17% -1,897.64% -707.23%
EBIT Margin		 0.00% 0.00% 0.00% -8,105.82% -1,699.21% -613.51%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -8,108.55% -1,701.55% -614.59%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.03% 100.14% 100.18%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -4,697.48% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -4,688.32% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 4,662.83% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -74.62% -57.48% -34.66% -34.78% -36.36%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,583.20% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -29.59% -27.91% -28.34%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -29.60% -27.94% -28.39%
Return on Common Equity (ROCE)		 0.00% 77.86% -40.30% -34.66% -34.78% -36.36%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 71.51% -33.67% -28.57% -33.37% -40.27%
Net Operating Profit after Tax (NOPAT)		 -9.55 -28 -61 -116 -156 -160
NOPAT Margin		 0.00% 0.00% 0.00% -5,975.32% -1,328.35% -495.06%
Net Nonoperating Expense Percent (NNEP)		 0.00% -47.88% -27.45% -9.17% -7.52% -6.73%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -20.61% -26.05% -32.44%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 1,933.69% 424.70% 175.20%
R&D to Revenue		 0.00% 0.00% 0.00% 6,702.47% 1,572.94% 632.03%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 8,636.17% 1,997.64% 807.23%
Earnings before Interest and Taxes (EBIT)		 -19 -46 -120 -157 -200 -198
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -19 -44 -117 -156 -209 -204
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.97 2.16 1.48 0.97
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.97 2.16 1.48 0.97
Price to Revenue (P/Rev)		 0.00 0.00 0.00 614.13 75.58 14.77
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 80.86 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 334.43 22.52 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.02 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.18 -1.03 -0.99 -1.01 -1.05
Leverage Ratio		 0.00 1.28 1.11 1.17 1.24 1.28
Compound Leverage Factor		 0.00 1.28 1.11 1.17 1.24 1.28
Debt to Total Capital		 0.00% 0.00% 0.00% 2.12% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 2.12% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 204.34% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -104.34% 100.00% 97.89% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.08 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 3.49 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.10 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 4.68 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 7.23 39.17 5.04 2.57 0.22
Noncontrolling Interest Sharing Ratio		 0.00% 204.34% 29.90% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.00 10.11 16.67 16.05 17.24 12.65
Quick Ratio		 0.00 9.86 16.37 15.81 16.86 12.22
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -18 -69 -127 -124 -154
Operating Cash Flow to CapEx		 -400.75% -1,029.94% -1,786.65% -924.52% -1,611.00% -4,220.88%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.02 0.05
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.15 0.57 1.57
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 -11 -3.09 8.03 -24 -31
Invested Capital Turnover		 0.00 0.00 0.00 0.79 -1.43 -1.17
Increase / (Decrease) in Invested Capital		 0.00 -11 7.77 11 -32 -6.43
Enterprise Value (EV)		 0.00 320 1,416 649 265 -47
Market Capitalization		 267 267 1,776 1,192 889 478
Book Value per Share		 $0.00 ($28.40) $7.42 $8.94 $9.40 $5.83
Tangible Book Value per Share		 $0.00 ($28.40) $7.42 $8.94 $9.40 $5.83
Total Capital		 0.00 61 357 563 600 493
Total Debt		 0.00 0.00 0.00 12 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -72 -360 -543 -624 -524
Capital Expenditures (CapEx)		 1.86 3.42 4.36 13 9.28 3.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -5.46 -15 -15 -23 -24
Debt-free Net Working Capital (DFNWC)		 0.00 67 345 540 601 500
Net Working Capital (NWC)		 0.00 67 345 528 601 500
Net Nonoperating Expense (NNE)		 9.75 17 59 41 44 39
Net Nonoperating Obligations (NNO)		 0.00 -72 -360 -543 -624 -524
Total Depreciation and Amortization (D&A)		 0.03 1.71 3.04 1.78 -8.93 -5.65
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -764.55% -195.67% -75.59%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 27,819.06% 5,110.93% 1,545.97%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 27,205.77% 5,110.93% 1,545.97%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($4.48) ($2.91) ($3.12) ($2.35)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 48.58M 54.02M 64.18M 84.72M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($4.48) ($2.91) ($3.12) ($2.35)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 48.58M 54.02M 64.18M 84.72M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($4.48) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 26.87M 61.83M 83.62M 88.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.55 -28 -61 -116 -156 -160
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -5,975.32% -1,328.35% -495.06%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -8,105.82% -1,699.21% -613.51%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -3.02% -0.50% -0.23% -0.03%

Quarterly Metrics And Ratios for Verve Therapeutics

This table displays calculated financial ratios and metrics derived from Verve Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 235.52% 408.30% 305.63% 219.73% 120.24% 154.28% 479.03%
EBITDA Growth		 -103.38% -40.24% -89.14% -41.13% -7.00% -18.68% 6.83% 8.11% -6.94% -0.55% 38.92%
EBIT Growth		 -98.65% -30.94% -72.30% -31.41% -1.11% -17.76% 6.44% 7.56% -9.49% -3.40% 36.35%
NOPAT Growth		 -86.62% -46.62% -82.49% -38.85% -19.32% -13.07% 2.43% -0.44% -8.74% -3.93% 35.55%
Net Income Growth		 -98.65% -31.11% -72.30% -31.84% -1.26% -17.69% 6.23% 7.74% -9.56% -3.48% 36.32%
EPS Growth		 -68.09% -108.64% -35.48% -3.57% 8.86% -4.55% 29.76% 32.18% 18.06% 15.94% 40.68%
Operating Cash Flow Growth		 -36.62% -17.29% -46.52% -79.24% 59.52% -23.68% 12.25% 28.78% -235.34% -0.41% 35.37%
Free Cash Flow Firm Growth		 -164.53% 0.00% -0.55% 11.81% 54.85% 88.12% 51.00% 78.57% -129.14% -520.58% -61.61%
Invested Capital Growth		 35.27% 359.81% -91.71% -25.36% -798.34% -404.53% -3,052.85% -1,187.18% -26.20% -26.31% -1.14%
Revenue Q/Q Growth		 0.00% 8.93% 38.74% 49.07% 48.93% 65.03% 10.71% 17.51% 2.59% 90.53% 152.11%
EBITDA Q/Q Growth		 -12.04% 5.25% -29.48% -2.67% 15.06% -5.10% -1.64% -1.27% 1.14% 1.18% 38.25%
EBIT Q/Q Growth		 -10.36% 9.20% -26.67% -3.52% 15.08% -5.75% -0.64% -2.28% -0.58% 0.13% 38.04%
NOPAT Q/Q Growth		 -3.95% -8.78% -22.11% -0.56% 10.67% -3.08% -5.37% -3.51% 3.28% 1.48% 34.66%
Net Income Q/Q Growth		 -10.36% 9.08% -26.51% -3.86% 15.24% -5.67% -0.79% -2.19% -0.66% 0.20% 37.98%
EPS Q/Q Growth		 5.95% 16.46% -27.27% -3.57% 17.24% 4.17% 14.49% 0.00% 0.00% 1.69% 39.66%
Operating Cash Flow Q/Q Growth		 -9.03% -12.74% -49.26% 2.31% 75.37% -244.42% -5.90% 20.71% -15.95% -3.13% 31.83%
Free Cash Flow Firm Q/Q Growth		 29.12% -38.20% 28.01% -25.05% 63.71% 63.64% -196.99% 45.32% -288.07% 1.53% 22.66%
Invested Capital Q/Q Growth		 -175.21% 390.13% -90.17% 248.04% -1,005.21% 1.65% 4.70% -28.14% -5.07% 1.56% 23.69%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -4,799.78% -4,174.70% -3,896.23% -2,683.52% -1,530.64% -974.75% -894.91% -771.22% -743.19% -385.45% -94.41%
Operating Margin		 -4,721.21% -4,714.43% -4,149.50% -2,799.00% -1,678.99% -1,048.76% -998.14% -879.24% -828.99% -428.65% -111.10%
EBIT Margin		 -4,864.37% -4,054.55% -3,701.92% -2,570.81% -1,465.86% -939.35% -853.91% -743.26% -728.75% -381.97% -93.87%
Profit (Net Income) Margin		 -4,864.37% -4,059.78% -3,701.92% -2,579.22% -1,468.01% -939.97% -855.77% -744.25% -730.27% -382.53% -94.11%
Tax Burden Percent		 100.00% 100.13% 100.00% 100.33% 100.15% 100.07% 100.22% 100.13% 100.21% 100.15% 100.26%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -2,594.37% -1,884.42% -3,316.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -2,592.66% -1,881.72% -3,313.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2,578.57% 1,858.65% 3,285.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -31.65% -15.80% -25.77% -31.39% -38.24% -34.78% -36.03% -38.10% -40.67% -36.36% -34.26%
Cash Return on Invested Capital (CROIC)		 0.00% -1,583.20% -2,437.56% -4,512.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -8.34% -14.80% -25.18% -30.61% -17.39% -15.43% -20.05% -23.79% -27.86% -17.64% -8.31%
Return on Assets (ROA)		 -8.34% -14.82% -25.18% -30.71% -17.41% -15.44% -20.10% -23.82% -27.92% -17.67% -8.33%
Return on Common Equity (ROCE)		 -31.65% -15.80% -25.77% -31.39% -38.24% -34.78% -36.03% -38.10% -40.67% -36.36% -34.26%
Return on Equity Simple (ROE_SIMPLE)		 -26.94% 0.00% -35.17% -41.32% -41.88% 0.00% -33.76% -35.28% -38.74% 0.00% -38.23%
Net Operating Profit after Tax (NOPAT)		 -31 -33 -41 -41 -37 -38 -40 -41 -40 -39 -26
NOPAT Margin		 -3,304.84% -3,300.10% -2,904.65% -1,959.30% -1,175.29% -734.13% -698.70% -615.47% -580.29% -300.05% -77.77%
Net Nonoperating Expense Percent (NNEP)		 -3.08% -1.70% -2.70% -3.44% -1.76% -1.81% -1.60% -1.66% -2.01% -1.88% -0.98%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.93% - - - -6.30% - - - -7.95% -5.42%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,032.51% 1,130.34% 894.09% 640.99% 374.91% 238.74% 248.69% 217.38% 201.56% 107.78% 45.95%
R&D to Revenue		 3,788.70% 3,684.09% 3,355.41% 2,258.00% 1,404.07% 910.01% 849.45% 761.86% 727.43% 420.86% 165.14%
Operating Expenses to Revenue		 4,821.21% 4,814.43% 4,249.50% 2,899.00% 1,778.99% 1,148.76% 1,098.14% 979.24% 928.99% 528.65% 211.10%
Earnings before Interest and Taxes (EBIT)		 -45 -41 -52 -54 -46 -48 -49 -50 -50 -50 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -42 -55 -56 -48 -50 -51 -52 -51 -50 -31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.76 2.16 1.75 2.50 1.84 1.48 1.45 0.75 0.81 0.97 0.86
Price to Tangible Book Value (P/TBV)		 3.76 2.16 1.75 2.50 1.84 1.48 1.45 0.75 0.81 0.97 0.86
Price to Revenue (P/Rev)		 2,216.38 614.13 266.56 213.53 110.80 75.58 52.75 19.84 16.79 14.77 6.81
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 80.86 485.36 254.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,623.58 334.43 114.48 128.49 47.17 22.52 14.97 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -0.99 -0.99 -0.99 -1.03 -1.01 -1.02 -1.03 -1.06 -1.05 -1.04
Leverage Ratio		 1.16 1.17 1.17 1.20 1.28 1.24 1.25 1.28 1.32 1.28 1.27
Compound Leverage Factor		 1.16 1.17 1.17 1.20 1.28 1.24 1.25 1.28 1.32 1.28 1.27
Debt to Total Capital		 0.00% 2.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 2.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 97.89% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 3.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 4.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.95 5.60 4.06 5.16 2.88 3.23 3.04 1.04 0.84 0.98 0.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.35 16.05 15.43 14.32 14.41 17.24 19.82 14.64 13.05 12.65 9.84
Quick Ratio		 18.98 15.81 15.16 14.00 14.03 16.86 19.38 14.27 12.66 12.22 9.56
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -32 -45 -32 -40 -15 -5.29 -16 -8.59 -33 -33 -25
Operating Cash Flow to CapEx		 -1,106.37% -662.08% -1,454.70% -1,801.73% -1,113.20% -1,861.78% -9,949.65% -3,485.51% -4,231.52% -2,944.85% -2,274.92%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.01 0.01 0.02 0.02 0.03 0.04 0.05 0.09
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.09 0.15 0.21 0.32 0.42 0.57 0.76 1.00 1.21 1.57 3.02
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.77 8.03 0.79 2.75 -25 -24 -23 -30 -31 -31 -24
Invested Capital Turnover		 -0.26 0.79 0.65 1.69 -0.55 -1.43 -1.43 -1.52 -0.87 -1.17 -2.54
Increase / (Decrease) in Invested Capital		 1.51 11 -8.73 -0.93 -22 -32 -24 -33 -6.51 -6.43 -0.27
Enterprise Value (EV)		 1,508 649 383 699 360 265 240 -166 -130 -47 -91
Market Capitalization		 2,059 1,192 892 1,161 845 889 847 410 410 478 406
Book Value per Share		 $9.14 $8.94 $8.24 $7.51 $7.22 $9.40 $7.01 $6.50 $6.01 $5.83 $5.33
Tangible Book Value per Share		 $9.14 $8.94 $8.24 $7.51 $7.22 $9.40 $7.01 $6.50 $6.01 $5.83 $5.33
Total Capital		 548 563 509 465 460 600 583 546 509 493 474
Total Debt		 0.00 12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -551 -543 -509 -462 -485 -624 -606 -576 -540 -524 -497
Capital Expenditures (CapEx)		 2.64 4.97 3.38 2.66 1.06 2.19 0.43 0.98 0.94 1.39 1.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -15 -24 -22 -22 -23 -17 -25 -26 -24 -37
Debt-free Net Working Capital (DFNWC)		 533 540 484 440 464 601 589 551 514 500 460
Net Working Capital (NWC)		 533 528 484 440 464 601 589 551 514 500 460
Net Nonoperating Expense (NNE)		 14 7.69 11 13 9.12 11 8.95 8.62 10 11 5.39
Net Nonoperating Obligations (NNO)		 -551 -543 -509 -462 -485 -624 -606 -576 -540 -524 -497
Total Depreciation and Amortization (D&A)		 0.60 -1.22 -2.73 -2.36 -2.02 -1.82 -2.34 -1.87 -0.99 -0.46 -0.18
Debt-free, Cash-free Net Working Capital to Revenue		 -1,948.12% -764.55% -731.00% -412.67% -282.45% -195.67% -108.01% -123.15% -107.00% -75.59% -62.75%
Debt-free Net Working Capital to Revenue		 57,331.75% 27,819.06% 14,476.38% 8,091.85% 6,080.33% 5,110.93% 3,670.21% 2,666.21% 2,106.15% 1,545.97% 771.09%
Net Working Capital to Revenue		 57,331.75% 27,205.77% 14,476.38% 8,091.85% 6,080.33% 5,110.93% 3,670.21% 2,666.21% 2,106.15% 1,545.97% 771.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.79) ($0.66) ($0.84) ($0.87) ($0.72) ($0.69) ($0.59) ($0.59) ($0.59) ($0.58) ($0.35)
Adjusted Weighted Average Basic Shares Outstanding		 57.21M 54.02M 61.79M 61.95M 63.21M 64.18M 83.13M 84.23M 84.63M 84.72M 88.80M
Adjusted Diluted Earnings per Share		 ($0.79) ($0.66) ($0.84) ($0.87) ($0.72) ($0.69) ($0.59) ($0.59) ($0.59) ($0.58) ($0.35)
Adjusted Weighted Average Diluted Shares Outstanding		 57.21M 54.02M 61.79M 61.95M 63.21M 64.18M 83.13M 84.23M 84.63M 84.72M 88.80M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.60M 61.83M 61.93M 63.72M 63.75M 83.62M 83.97M 84.62M 84.66M 88.80M 89.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -33 -41 -41 -37 -38 -40 -41 -40 -39 -26
Normalized NOPAT Margin		 -3,304.84% -3,300.10% -2,904.65% -1,959.30% -1,175.29% -734.13% -698.70% -615.47% -580.29% -300.05% -77.77%
Pre Tax Income Margin		 -4,864.37% -4,054.55% -3,701.92% -2,570.81% -1,465.86% -939.35% -853.91% -743.26% -728.75% -381.97% -93.87%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.41% -0.50% -0.47% 0.00% 0.00% -0.23% -0.23% -0.24% 0.00% -0.03% -0.01%

Key Financial Trends

Verve Therapeutics has accelerated its revenue trajectory over the past year while steadily narrowing its net losses and improving operating cash flow. The company ended Q1 2025 with a strong cash position and ample liquidity, though it remains unprofitable with high expense ratios typical of a clinical-stage biotech. Below are key factors that may influence the stock.

  • Revenue jumped to $32.98 M in Q1 2025, up 4.79% sequentially and more than doubling year-over-year
  • Net loss improved by ~36% year-over-year in Q1 2025, reflecting narrowing operating shortfall
  • Operating cash burn declined to $27.85 M in Q1 2025 from $40.84 M in Q4 2024
  • Strong liquidity: $96.6 M in cash and $400.5 M in short-term investments, net cash position of $497 M
  • Price-to-book fell to 0.86× in Q1 2025 from 0.97× in Q4 2024, suggesting potential undervaluation
  • R&D and SG&A expenses remain elevated at 165% and 46% of revenue in Q1 2025
  • Free cash flow to firm stayed negative at –$25.4 M in Q1 2025, despite sequential improvement
  • Altman Z-score of 0.80 is below the benchmark for financial distress, but cash buffers mitigate short-term risk
  • Profit margin was –94% in Q1 2025, underscoring ongoing unprofitability
  • Consistent quarterly net losses (~$31 M in Q1 2025) require additional financing to sustain operations
06/21/25 11:28 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Verve Therapeutics' Financials

When does Verve Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Verve Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Verve Therapeutics' net income changed over the last 5 years?

Verve Therapeutics' net income appears to be on an upward trend, with a most recent value of -$198.71 million in 2024, rising from -$19.30 million in 2019. The previous period was -$200.07 million in 2023. View Verve Therapeutics' forecast to see where analysts expect Verve Therapeutics to go next.

What is Verve Therapeutics' operating income?
Verve Therapeutics' total operating income in 2024 was -$228.66 million, based on the following breakdown:
  • Total Gross Profit: $32.33 million
  • Total Operating Expenses: $260.99 million
How has Verve Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Verve Therapeutics' total revenue changed from $0.00 in 2019 to $32.33 million in 2024, a change of 3,233,200,000.0%.

How much debt does Verve Therapeutics have?

Verve Therapeutics' total liabilities were at $153.99 million at the end of 2024, a 0.5% increase from 2023, and a 797.3% increase since 2020.

How much cash does Verve Therapeutics have?

In the past 4 years, Verve Therapeutics' cash and equivalents has ranged from $8.99 million in 2020 to $206.18 million in 2023, and is currently $172.56 million as of their latest financial filing in 2024.

How has Verve Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Verve Therapeutics' book value per share changed from 0.00 in 2019 to 5.83 in 2024, a change of 582.8%.


Related Companies

This page (NASDAQ:VERV) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...
American Alternative | Sponsored
The IRS Loophole That Lets You Own Gold Tax-Free
What if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...
Advantage Gold | Sponsored